Results 261 to 270 of about 1,682,964 (357)

Therapeutic Prospects of αv Integrins Inhibition in Fibrotic Lung Diseases and Carcinogenesis. [PDF]

Int J Mol Sci
Golovina EL, Kochubey VV, Shabanova MA, Chekhvalova DM, Serebryakova VA, Skurikhin EG, Vaizova OE, Morozov SG, Kubatiev AA, Dygai AM.   +9 more
europepmc   +1 more source

Machine Learning‐Enabled Polymer Discovery for Enhanced Pulmonary siRNA Delivery

Advanced Functional Materials, EarlyView.
This study provides an efficient approach to train a machine learning model by merging heterogeneous literature data to predict suitable polymers for siRNA delivery. Without the need for extensive laboratory synthesis, the machine learning enabled a virtual screening and successfully predicted a polymer that is validated for effective gene silencing in
Felix Sieber‐Schäfer, Min Jiang, Adrian Kromer, Anny Nguyen, Müge Molbay, Simone Pinto Carneiro, David Jürgens, Gerald Burgstaller, Bastian Popper, Benjamin Winkeljann, Olivia Monika Merkel   +10 more
wiley   +1 more source

Intravenous Immunoglobulin in Acute Exacerbations of Fibrotic Interstitial Lung Diseases: A Retrospective, Real-World Study. [PDF]

Medicina (Kaunas)
Sotiropoulou V, Theochari E, Katsaras M, Tsiri P, Komninos D, Christopoulos I, Tsirikos G, Kalogeropoulou C, Daoussis D, Karkoulias K, Sampsonas F, Tzouvelekis A.   +11 more
europepmc   +1 more source

On Diseases of the Lungs

Jesús Duarte M
openalex   +1 more source

Adalimumab‐Poloxamer Conjugate for Bio‐Better: Enhanced Stability and Function

Advanced Functional Materials, EarlyView.
Antibody‐polymer conjugates, particularly poloxamer conjugates, enhance antibody stability by improving tolerance to physicochemical stress and attenuating proteolysis by proteases. Furthermore, the higher affinity observed with poloxamer conjugation compared to standard PEGylation results in improved therapeutic efficacy in rheumatoid arthritis mouse ...
Jaewon Roh, Sanghee Lee, Soomin Cho, Kun Na   +3 more
wiley   +1 more source

Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases. [PDF]

Pharmaceutics
Mahmoud DE, Hosseini SH, Rathore HA, Alkilany AM, Heise A, Elhissi A.   +5 more
europepmc   +1 more source

Perfusable Brain Microvascular Network‐On‐Chip Model to Study Flavivirus NS1‐Induced Endothelial Dysfunction

Advanced Functional Materials, EarlyView.
This study presents a microfluidic brain microvascular network‐on‐chip (BMVasChip) to investigate endothelial barrier dysfunction caused by flavivirus non‐structural protein 1 (NS1), including virus‐ and time‐dependent vascular damage, leakiness, and dysfunction.
Monika Rajput, Yen‐Ting Tung, Yu‐Chi Chen, Min Jae Song, Marc Ferrer, Emily M. Lee   +5 more
wiley   +1 more source

Race and ethnicity in fibrotic interstitial lung diseases: what do these categories contribute in the clinical setting? [PDF]

ERJ Open Res
Suzuki A.
europepmc   +1 more source

Endocytic Programming via Porous Silicon Nanoparticles Enhances TLR4 Nanoagonist Potency for Macrophage‐Mediated Immunotherapy

Advanced Functional Materials, EarlyView.
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang, Huiying Li, Shuodan Huang, Linxuan Zhang, Yan Gao, Ruoran Wang, Xiaoyu Wang, Hélder A. Santos, Zhenyu Yin, Bing Xia   +9 more
wiley   +1 more source

The necessity of geneticist and pulmonologist collaboration in the treatment of monogenic interstitial lung diseases in adults. [PDF]

Breathe (Sheff)
Sterclova M, Doubkova M, Doubek M, Macek M.   +3 more
europepmc   +1 more source